NASDAQ · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · SMALL CAP
enGene Therapeutics Inc. ENGN
4 fiscal years on record · USD · FY2025 reported · SEC filings only
$-117.3M
$-100.7M
Growth
—
Revenue, FY2025 · full 4-year series below
Compound annual growth
3 yrs
5 yrs
10 yrs
15 yrs
Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.
Profitability
—
ROE
FY2025 · ROE -53.3%
Each USD of equity lost 53 cents this year.
The 4-year record
4 fiscal years
Every figure from documents filed with the SEC · USD
EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.
row low → row highnegative
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Revenue $B | · | · | · | · |
| Operating income $B | −0.1 | −0.1 | −0.0 | −0.0 |
| EBITDA $B | −0.1 | −0.1 | −0.0 | −0.0 |
| Income tax $B | 0.0 | −0.0 | 0.0 | 0.0 |
| Net income $B | −0.1 | −0.1 | −0.1 | −0.0 |
| Free cash flow $B | −0.1 | −0.0 | −0.0 | −0.0 |
| EPS, diluted $ | −2.29 | −1.46 | 151.22 | 44.30 |
| Dividend / sh $ | 0.00 | 0.00 | 0.00 | · |
| Payout % | · | · | −0 | · |
| ROE % | −53.3 | −32.0 | · | · |
| Shares out B | 0.05 | 0.05 | 0.02 | 0.00 |
Slide the table for earlier years · "·" marks a figure not available in our data for that year.
Provenance
Company facts, as filed
How we verify · 2 failures in 16 reconciliationsAUDITED
Reconciled in 2 of 19 fiscal years. 60 checks could not be computed.
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente2 failures
ActivityBiological Products, (No Diagnostic Substances)
Listed onNASDAQ
Incorporated inoutside the United States — SEC code Z4
Fiscal year endsOctober 31
SEC categoryemerging growth company, smaller reporting company
Data on record since2022